COMPANY

Starlight Cardiovascular

HQ: San Diego, CA source · starlightcardio.com ↗ · West Coast

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: congenital heart defect hypoplastic left heart syndrome Congenital Heart Disease

1Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $500K (SBIR commercialization 1SB1HL184388-01, new, notice Aug 10, 2026); 3 NIH awards totaling $2.67M in the last 12 months. NIH RePORTER 1SB1HL184388-01 (Aug 10, 2026)
Evidence (3 events)
- Aug 10, 2026 · NIH RePORTER 1SB1HL184388-01
  Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 1SB1HL184388-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 499952; Administering IC: National Heart Lung and Blood Institute; Project title: Commercialization Readiness of a Pulmonary Flow Restrictor for Hypoplastic Left Heart Syndrome; Organization type: Domestic For-Profits
- Aug 3, 2026 · NIH RePORTER 2R44HL162218-04
  Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 2R44HL162218-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1166665; Administering IC: National Heart Lung and Blood Institute; Project title: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME; Organization type: Domestic For-Profits
- May 13, 2026 · NIH RePORTER 5R44HL158304-05
  Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 5R44HL158304-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999876; Administering IC: National Heart Lung and Blood Institute; Project title: DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 10, 2026 Grant Government grant — SBIR: $499,952 (annual award, as published), announced Aug 10, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 3, 2026 Grant Government grant — SBIR: $1.17M (annual award, as published), announced Aug 3, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
May 13, 2026 Grant Government grant — SBIR: $999,876 (annual award, as published), announced May 13, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Jan 16, 2026 Trial start Not phased (device or behavioral study): Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study source ↗
Feb 20, 2025 Grant Government grant — SBIR: $999,901 (annual award, as published), announced Feb 20, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Dec 9, 2024 Grant Government grant — SBIR: $999,918 (annual award, as published), announced Dec 9, 2024. Agency: NIH/NHLBI. Source: government award database. source ↗

Upcoming milestones

2027-10 (ESTIMATED) · Not phased · Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study · NCT07114718

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Aug 10, 2026 Government grant — SBIR: $499,952 (annual award, as published), announced Aug 10, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Aug 3, 2026 Government grant — SBIR: $1.17M (annual award, as published), announced Aug 3, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
May 13, 2026 Government grant — SBIR: $999,876 (annual award, as published), announced May 13, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Feb 20, 2025 Government grant — SBIR: $999,901 (annual award, as published), announced Feb 20, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗
Dec 9, 2024 Government grant — SBIR: $999,918 (annual award, as published), announced Dec 9, 2024. Agency: NIH/NHLBI. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07114718	Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study	Not phased (device or behavioral study)	Recruiting	Jan 16, 2026	2027-10 (estimated)

NIH awards 7

Annual award amounts. Total $4.7M.

Sep 15, 2024 NIH award 1SB1HL176266-01 FY2024: $500,000 awarded for that fiscal year; activity SB1 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. Commercialization Readiness for Duc source ↗
Jun 11, 2024 NIH award 3R44HL162218-02A1S1 FY2024: $88,483 awarded for that fiscal year; activity R44 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. Administrative Supplement to Pro source ↗
Mar 20, 2024 NIH award 2R44HL162218-02A1 FY2024: $999,969 awarded for that fiscal year; activity R44 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. DEVELOPMENT OF A PULMONARY FLOW R source ↗
Jul 14, 2023 NIH award 5R44HL158304-03 FY2023: $901,548 awarded for that fiscal year; activity R44 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. DUCTUS ARTERIOSUS STENT TO IMPROVE source ↗
Sep 19, 2022 NIH award 2R44HL158304-02 FY2022: $1,256,635 awarded for that fiscal year; activity R44 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. DUCTUS ARTERIOSUS STENT TO IMPROV source ↗
Feb 15, 2022 NIH award 1R43HL162218-01 FY2022: $448,000 awarded for that fiscal year; activity R43 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. DEVELOPMENT OF A PULMONARY FLOW RES source ↗
Aug 6, 2021 NIH award 1R43HL158304-01A1 FY2021: $492,571 awarded for that fiscal year; activity R43 (SBIR); PI TANG, BEVERLY; recipient as written: STARLIGHT CARDIOVASCULAR, INC., San Diego, CA. DUCTUS ARTERIOSUS STENT TO IMPROV source ↗